← peptides typeshit

Vanda's NEREUS cut GLP-1 vomiting by 27% in a Phase III trial

Vomiting hit 43% on tradipitant versus 58.5% on placebo after a single semaglutide dose. Vanda plans to seek FDA approval for the new use.

Read at BioBuzz

Recap by typeshit. Full story at BioBuzz.